BUILD-3 study with bosentan in idiopathic pulmonary fibrosis does not meet primary endpoint
02-Mar-2010 -
Actelion Ltd announced the initial results of BUILD-3, a clinical study evaluating the safety and efficacy of bosentan in patients suffering from idiopathic pulmonary fibrosis. While there was a consistent trend in favor of bosentan, the primary endpoint, reduction in morbidity/mortality, was ...
Actelion
fibrosis
idiopathic pulmonary fibrosis
+2